- Fluidigm (FLDM) inks an agreement with Baylor Genetics securing the rights to commercialize its CFTR library prep assay for research use with the automated Juno microfluidic system. The targeted next-generation sequencing (NGS) assay identifies variants from each of the 27 exons in the CFTR gene and selected areas within the gene. Mutations in the CFTR gene are responsible for cystic fibrosis.
- Financial terms are not disclosed.
Fluidigm in-licenses next-gen sequencing assay from Baylor Genetics targeting cystic fibrosis gene
Recommended For You
More Trending News
About LAB Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
LAB | - | - |
Standard BioTools Inc. |